Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
e-Letters: Observations

Congenital Anomalies in Offspring of Maternal Glucokinase–Maturity-Onset Diabetes of the Young: A Case Report

  1. Victoria L. Rudland1,2⇑,
  2. Jason Pinner3 and
  3. Glynis P. Ross1,2
  1. 1Faculty of Medicine and Health, The University of Sydney, Sydney, Australia
  2. 2Department of Endocrinology, Royal Prince Alfred Hospital, Sydney, Australia
  3. 3Department of Medical Genomics, Royal Prince Alfred Hospital, Sydney, Australia
  1. Corresponding author: Victoria L. Rudland, vrudland{at}med.usyd.edu.au
Diabetes Care 2019 Oct; 42(10): e162-e163. https://doi.org/10.2337/dc19-0930
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

A 24-year-old white European woman with diet-treated diabetes since 15 years of age presented prior to her first pregnancy. Her prepregnancy HbA1c was 5.8% (40 mmol/mol), and HbA1c at 12 weeks’ gestation was 6.0% (42 mmol/mol). She received insulin therapy from 13 weeks (up to 0.3 units/kg/day) and had a vaginal delivery of a boy weighing 3,205 g (84th centile) at 37 weeks. He had neonatal jaundice and bilateral vesicoureteral reflux requiring reimplantation surgery (Table 1).

View this table:
  • View inline
  • View popup
Table 1

Details of GCK-MODY pregnancies in this case report

Her second pregnancy was managed similarly, with insulin therapy from 4 weeks’ gestation (up to 0.7 units/kg/day). The HbA1c was 5.5% (37 mmol/mol) at 8 weeks. She had a vaginal delivery of a healthy girl weighing 3,235 g (33rd centile) following induction of labor at 40 weeks.

Postpartum, the mother’s persistent fasting hyperglycemia, small increment on a 75-g oral glucose tolerance test (6.2, 7.7, and 6.3 mmol/L [fasting, 1 h, and 2 h, respectively]), and two-generation family history of diabetes suggested glucokinase–maturity-onset diabetes of the young (GCK-MODY), which was confirmed on genetic testing (heterozygous glucokinase (GCK) mutation c.952G>A, p.Gly318Arg).

Her third pregnancy was managed at another institution with diet alone. The HbA1c was 6.5% (48 mmol/mol) at 5 weeks’ gestation. Third trimester fetal ultrasounds suggested accelerating abdominal circumference (50th to 95th centile). She developed obstructed labor at 40 weeks and delivered a boy weighing 4,200 g (97th centile) via cesarean section. He has trivial pulmonary valve stenosis.

Subsequent genetic testing of all three children demonstrated that the second child had inherited the GCK mutation, whereas the first and third children did not have the GCK mutation.

GCK-MODY is an autosomal dominant condition caused by heterozygous inactivating mutations in the GCK gene. For individuals with GCK-MODY, the glucose threshold for insulin release is set 1.0–2.5 mmol/L higher than that of normal subjects. As a result, they have mild fasting hyperglycemia (5.5–8.0 mmol/L), and glucose perturbations are regulated to the higher set point. Diabetes-related complications are relatively uncommon, so treatment of the hyperglycemia is not usually indicated, except in pregnancy.

The management approach for GCK-MODY in relation to pregnancy is designed to improve neonatal outcomes. As in type 1 and type 2 diabetes, maternal GCK-MODY can increase the risk of macrosomia and attendant complications. However, whether maternal GCK-MODY increases the risk of congenital anomalies is unclear.

It is well documented that maternal GCK-MODY can increase fetal growth. For each pregnancy, there is a 50% chance that the fetus will inherit the GCK mutation. Fetal growth is predominantly determined by fetal genotype, more so than by treatment of maternal hyperglycemia (1). If the fetus inherits the GCK mutation, the fetus will regulate its blood glucose levels to the same elevated set point as its mother and normal fetal growth ensues (1), as demonstrated in the second child in the present case. Treatment of maternal hyperglycemia could adversely reduce fetal growth and therefore is not recommended. Conversely, if the fetus does not inherit the GCK mutation, maternal hyperglycemia will stimulate insulin-mediated fetal growth, which increases the risk of macrosomia, cesarean section, and neonatal hypoglycemia, as demonstrated in the first and third children in the present case, and insulin treatment is recommended (1). The fetal genotype is usually unknown during pregnancy, so serial fetal ultrasounds are recommended to monitor fetal growth and guide management. For the third child, acceleration of the fetal abdominal circumference suggested that the fetus had not inherited the GCK mutation and should have prompted intensive insulin therapy (>1 unit/kg/day).

For offspring of mothers with type 1 or type 2 diabetes, the rate of congenital anomalies increases linearly with increasing maternal HbA1c >6.3% (45 mmol/mol), with no difference in risk by type of diabetes (2). However, at lower early pregnancy HbA1c >5.6% (38 mmol/L), there is also evidence for an increased risk (3). For individuals with GCK-MODY, the HbA1c is typically 5.6–7.6% (38–60 mmol/mol) (4). It is, therefore, plausible that maternal hyperglycemia secondary to GCK-MODY, while relatively mild, may be sufficient to contribute to congenital anomalies in offspring who have not inherited the GCK mutation.

Recently, a case of sacral agenesis in a fetus of a woman with GCK-MODY was reported (5). However, the fetal genotype was unknown. In the present case, the fetal GCK genotype of all three children was confirmed. Congenital anomalies occurred in the two offspring who had not inherited the GCK mutation. Although the co-occurrence of maternal GCK-MODY and congenital anomalies does not establish causality, it raises the possibility that GCK-MODY could contribute to pathogenesis in offspring who have not inherited the GCK mutation. Consideration should be given for preconception high-dose folic acid in women with GCK-MODY and establishment of an international GCK-MODY register to monitor pregnancy outcomes.

Article Information

Acknowledgments. The patient provided consent to publication of her case. The authors thank Andrew T. Hattersley (University of Exeter, Exeter, U.K.), who advised on the case and arranged genetic testing.

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Author Contributions. V.L.R. wrote the manuscript. J.P. reviewed and edited the manuscript, advised on the case, and arranged genetic testing. G.P.R. reviewed and edited the manuscript and was responsible for the clinical management of the case during the first two pregnancies. G.P.R. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

  • Received May 9, 2019.
  • Accepted July 5, 2019.
  • © 2019 by the American Diabetes Association.
http://www.diabetesjournals.org/content/license

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

References

  1. ↵
    1. Spyer G,
    2. Macleod KM,
    3. Shepherd M,
    4. Ellard S,
    5. Hattersley AT
    . Pregnancy outcome in patients with raised blood glucose due to a heterozygous glucokinase g ene mutation. Diabet Med 2009;26:14–18
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Bell R,
    2. Glinianaia SV,
    3. Tennant PW,
    4. Bilous RW,
    5. Rankin J
    . Peri-conception hyperglycaemia and nephropathy are associated with risk of congenital anomaly in women with pre-existing diabetes: a population-based cohort study. Diabetologia 2012;55:936–947
    OpenUrlCrossRefPubMed
  3. ↵
    1. Suhonen L,
    2. Hiilesmaa V,
    3. Teramo K
    . Glycaemic control during early pregnancy and fetal malformations in women with type I diabetes mellitus. Diabetologia 2000;43:79–82
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Steele AM,
    2. Wensley KJ,
    3. Ellard S, et al
    . Use of HbA1c in the identification of patients with hyperglycaemia caused by a glucokinase mutation: observational case control studies. PLoS One 2013;8:e65326
    OpenUrlCrossRefPubMed
  5. ↵
    1. Taylor RAM,
    2. Mackie A,
    3. Mogra R,
    4. Pinner J,
    5. Rajendran S,
    6. Ross GP
    . Caudal regression syndrome in a fetus of a glucokinase-maturity-onset diabetes of the young pregnancy. Diabet Med 2019;36:252–255
    OpenUrl
PreviousNext
Back to top
Diabetes Care: 42 (10)

In this Issue

October 2019, 42(10)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Congenital Anomalies in Offspring of Maternal Glucokinase–Maturity-Onset Diabetes of the Young: A Case Report
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Congenital Anomalies in Offspring of Maternal Glucokinase–Maturity-Onset Diabetes of the Young: A Case Report
Victoria L. Rudland, Jason Pinner, Glynis P. Ross
Diabetes Care Oct 2019, 42 (10) e162-e163; DOI: 10.2337/dc19-0930

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Congenital Anomalies in Offspring of Maternal Glucokinase–Maturity-Onset Diabetes of the Young: A Case Report
Victoria L. Rudland, Jason Pinner, Glynis P. Ross
Diabetes Care Oct 2019, 42 (10) e162-e163; DOI: 10.2337/dc19-0930
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Article Information
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Interferent Effect of Hydroxyurea on Continuous Glucose Monitoring
  • Creating Composite Indices From Continuous Variables for Research: The Geometric Mean
  • Continuous Glucose Monitoring in the Operating Room and Cardiac Intensive Care Unit
Show more e-Letters: Observations

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.